

VIVALIS GRANTS RESEARCH LICENCE TO ACAMBIS TO EVALUATE EB66[®] CELL LINE FOR VIRAL VACCINES PRODUCTION

Nantes (France) – Cambridge (USA), July 8th, 2008 – VIVALIS (NYSE Euronext : VLS) announced today that it has granted ACAMBIS INC. (LSE : ACM) rights to the avian embryonic stem cell derived **EB66[®]** cell line to evaluate it as a production platform of viral vectors and vaccines.

"VIVALIS is pleased to enter in this agreement to support ACAMBIS' R&D efforts for the development of new vaccines. With already more than 30 different vaccines evaluated or developed on VIVALIS **EB66[®]** cell line, we strongly believe that this cell line has the potential to replace the eggs, and to become a standard cell substrate for vaccines production in the foreseeable future", said Franck GRIMAUD, VIVALIS CEO.

Terms of the agreement were not disclosed.

Next press release:

13 August 2008, after closure of the Euronext Paris market: Turnover for the 2nd quarter of 2008

About Acambis (www.acambis.com)

Acambis (Cambridge, UK and Cambridge, MA, USA) is a vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve standards of care. It has a broad pipeline of novel vaccine candidates, including:

- the only single-dose vaccine in development against Japanese encephalitis;
- the leading vaccine in development against the West Nile virus;
- a tetravalent dengue vaccine that has achieved proof-of-concept by generating 100% seroconversion to all four dengue virus serotypes;
- the only vaccine in development against *Clostridium difficile* bacteria, a leading cause of hospital-acquired infections;
- a novel influenza vaccine that provides a universal approach to tackling 'A' strains of the virus; and
- a replication-deficient vaccine, *d15-29*, against genital herpes.

Acambis has partnerships with sanofi pasteur for the development and commercialisation of its JE, West Nile and dengue vaccines. It is recognised internationally as the leading producer of smallpox vaccines for emergency-use stockpiles held by the US Government and several other governments around the world. Acambis developed its ACAM2000[™] smallpox vaccine under contracts with the US Government.

Acambis Inc. is the US-based subsidiary of Acambis plc, which is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com.

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS's expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of viral vaccines. Vivalis receive up front, milestones and royalties [payments](#) on its licensees net sales.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EB66® cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receive up front, milestones, and royalties [payments](#) on its licensees net sales.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established numerous partnerships with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

Euronext Paris Compartment C - FR0004056851
Reuters: **VLS.PA** – Bloomberg: **VLS FP**

Investor relations:

VIVALIS
Franck Grimaud, C.E.O.
Email: investors@vivalis.com

NewCap
Financial Communication Agency
Steve Grobet / Emmanuel Huynh
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr